Propanc Biopharma’s Stock Plummets Amid Financial Struggles Despite Innovative Cancer Therapy Promise
Propanc Biopharma’s stock has experienced a dramatic rollercoaster ride, plummeting from a 52-week high of $222 to a low of $1.25, amidst concerns over the company’s financial health and the high-risk, high-reward nature of its biotech endeavors.
3 minutes to read